CoChat

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study

Open access
Kosiborod, Mikhail, Birkeland, Kåre I., Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Holl, Reinhard W., Norhammar, Anna, Jørgensen, Marit E., Wittbrodt, Eric T., Thuresson, Marcus, Bodegård, Johan, Hammar, Niklas, Fenici, Peter, the CVD‐REAL Investigators and Study Group · 2018 · Diabetes, Obesity and Metabolism
Cited by 82

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The multinational, observational CVD‐REAL study recently showed that initiation of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2i) was associated with significantly lower rates of death and heart failure vs other glucose‐lowering drugs (oGLDs). This sub‐analysis of the CVD‐REAL study sought to determine the association between initiation of SGLT‐2i vs oGLDs and rates of myocardial infarction (MI) and stroke. Medical records, claims and national registers from the USA, Sweden, Norway and Denmark were used to identify patients with T2D who newly initiated treatment with SGLT‐2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs. A non‐parsimonious propensity score was developed within each country to predict initiation of SGLT‐2i, and patients were matched 1:1 in the treatment groups. Pooled hazard ratios (HRs) and 95% CIs were generated using Cox regression models. Overall, 205 160 patients were included. In the intent‐to‐treat analysis, over 188 551 and 188 678 person‐years of follow‐up (MI and stroke, respectively), there were 1077 MI and 968 stroke events. Initiation of SGLT‐2i vs oGLD was associated with a modestly lower risk of MI and stroke (MI: HR, 0.85; 95%CI, 0.72‐1.00; P = .05; Stroke: HR, 0.83; 95% CI, 0.71‐0.97; P = .02). These findings complement the results of the cardiovascular outcomes trials, and offer additional reassurance with regard to the cardiovascular effects of SGLT‐2i, specifically as it relates to ischaemic events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13299

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 82

Metadata

Authors
Kosiborod, M., Birkeland, K. I., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Jørgensen, M. E., Wittbrodt, E. T., Thuresson, M., Bodegård, J., Hammar, N., Fenici, P., & the CVD‐REAL Investigators and Study Group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-04-17
Volume
20
Issue
8
Pages
1983-1987
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2800277129
Cited by
82
References
7
FWCI
9.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study. https://app.cochat.ai/papers/10.1111/dom.13299
The paper
Kosiborod, M., Birkeland, K. I., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Jørgensen, M. E., Wittbrodt, E. T., Thuresson, M., Bodegård, J., Hammar, N., Fenici, P., & the CVD‐REAL Investigators and Study Group. (2018). Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.